Cycle Pharmaceuticals Partners for U.S. Commercial Supply of FDA-Approved CAVHANZA for CML

Cycle Pharmaceuticals has selected Forma Life Sciences to establish U.S. commercial supply for its FDA-approved CAVHANZA™ (nilotinib) orally disintegrating tablets. CAVHANZA is an FDA-approved treatment for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This new formulation addresses key administration challenges associated with conventional nilotinib products, as it can be administered with proton pump inhibitors and H2 receptor antagonists without timing restrictions, and clinical studies showed no food effect. This development aims to improve treatment accessibility and adherence for CML patients.